Trial Profile
A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients With Stage IV HER2-negative Inflammatory Breast Cancer (IBC) and Local or Distant Relapse
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Therapeutic Use
- 22 Jul 2019 Status changed from active, no longer recruiting to completed.
- 23 May 2017 Status changed from completed to active, no longer recruiting.
- 01 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.